Original Article

Assessments the binding affinity of the corresponding ligands of tumor specific antigen of prostate cancer, opportunity for immunotoxin development

Mohammad RastegarMoghadam-Baghestani, Aliakbar Haddad-Mashadrizeh , Javad Baharara

Mohammad RastegarMoghadam-Baghestani
Department of Biology, Science and Research branch, Islamic Azad University, Khorasan Razavi, Neyshabur, Iran

Aliakbar Haddad-Mashadrizeh
Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran. Email: a.haddad@um.ac.ir

Javad Baharara
Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran
Online First: December 30, 2017 | Cite this Article
RastegarMoghadam-Baghestani, M., Haddad-Mashadrizeh, A., Baharara, J. 2017. Assessments the binding affinity of the corresponding ligands of tumor specific antigen of prostate cancer, opportunity for immunotoxin development. The Cancer Press 3(4). DOI:10.15562/tcp.21


Prostate cancer is the third major cause of death in men worldwide after lung cancer, cardiovascular disease and is known in two decades. Since 1987, the first treatment for prostate cancer was initiated in the wake of the global health So far safer and effective methods to treat this life threatening condition is better. During the past two decades scientists to develop drugs targeted therapies in cancer research priorities were. These therapies primarily based on a specific antigen in tumor tissues will be deployed. Prostate cancer-specific antigens of the most valuable PSMA (Prostate specific membrane antigen) is. In this study, to evaluate the PSMA binding affinity ligands can be connected to evaluate and recommend the best ligand for use in targeted drugs .

 

No Supplementary Material available for this article.
Article Views      : 177
PDF Downloads : 34